Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on April 1, 2025. The awards, approved by the Compensation Committee under the company's 2024 Inducement Plan, consist of non-qualified share options to purchase a total of 32,400 ordinary shares.
The options were granted at an exercise price of $8.49 per share, matching Bicycle's closing trading price on March 31, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment.
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato l'assegnazione di premi di indennità a otto nuovi dipendenti il 1° aprile 2025. I premi, approvati dal Comitato per la Compensazione nell'ambito del Piano di Indennità 2024 dell'azienda, consistono in opzioni su azioni non qualificate per l'acquisto di un totale di 32.400 azioni ordinarie.
Le opzioni sono state concesse a un prezzo di esercizio di $8,49 per azione, corrispondente al prezzo di chiusura delle azioni di Bicycle del 31 marzo 2025. Il piano di maturazione si estende su quattro anni, con il 25% che matura dopo un anno e le azioni rimanenti che maturano mensilmente nei successivi 36 mesi, a condizione di continuare l'impiego.
Bicycle Therapeutics (NASDAQ: BCYC) ha anunciado la concesión de premios de inducción a ocho nuevos empleados el 1 de abril de 2025. Los premios, aprobados por el Comité de Compensación bajo el Plan de Inducción 2024 de la empresa, consisten en opciones de acciones no calificadas para comprar un total de 32,400 acciones ordinarias.
Las opciones se otorgaron a un precio de ejercicio de $8.49 por acción, coincidiendo con el precio de cierre de las acciones de Bicycle el 31 de marzo de 2025. El calendario de adquisición se extiende por cuatro años, con el 25% adquiriendo derechos después de un año y las acciones restantes adquiriendo derechos mensualmente durante los siguientes 36 meses, sujeto a la continuación del empleo.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 2025년 4월 1일에 8명의 새로운 직원에게 유인 보상을 부여했다고 발표했습니다. 이 보상은 회사의 2024 유인 계획에 따라 보상 위원회에서 승인된 것으로, 총 32,400주의 비자격 주식 옵션으로 구성됩니다.
옵션은 주당 $8.49의 행사 가격으로 부여되었으며, 이는 2025년 3월 31일의 바이시클 종가와 일치합니다. 권리 부여 일정은 4년에 걸쳐 있으며, 1년 후 25%가 부여되고 나머지 주식은 이후 36개월 동안 매달 부여됩니다. 계속 고용되는 것을 전제로 합니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé l'octroi de primes d'incitation à huit nouveaux employés le 1er avril 2025. Les primes, approuvées par le Comité de Rémunération dans le cadre du Plan d'Incitation 2024 de l'entreprise, consistent en des options d'achat d'actions non qualifiées pour un total de 32 400 actions ordinaires.
Les options ont été accordées à un prix d'exercice de 8,49 $ par action, correspondant au prix de clôture de Bicycle du 31 mars 2025. Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % d'acquisition après un an et les actions restantes acquérant des droits mensuellement au cours des 36 mois suivants, sous réserve d'un emploi continu.
Bicycle Therapeutics (NASDAQ: BCYC) hat am 1. April 2025 die Vergabe von Induktionsprämien an acht neue Mitarbeiter bekannt gegeben. Die Prämien, die vom Vergütungsausschuss im Rahmen des Induktionsplans 2024 des Unternehmens genehmigt wurden, bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von insgesamt 32.400 Stammaktien.
Die Optionen wurden zu einem Ausübungspreis von 8,49 $ pro Aktie gewährt, was dem Schlusskurs von Bicycle am 31. März 2025 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25 % nach einem Jahr und die verbleibenden Aktien monatlich über die folgenden 36 Monate fällig werden, vorausgesetzt, das Arbeitsverhältnis wird fortgesetzt.
- None.
- None.
Each option has an exercise price equal to
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402649574/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
How many shares are included in Bicycle Therapeutics' (BCYC) April 2025 inducement grants?
What is the exercise price for BCYC's April 2025 inducement stock options?
What is the vesting schedule for BCYC's April 2025 inducement grants?
How many employees received BCYC inducement grants in April 2025?
